Wordt geladen...
Current treatment of atypical hemolytic uremic syndrome
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/ https://ncbi.nlm.nih.gov/pubmed/25343125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|